Adalimumab in Patients with Active Noninfectious Uveitis

This phase 3 trial showed that persons with noninfectious uveitis who received adalimumab were more likely to have serious adverse events and less likely to have ophthalmic inflammation, uveitic flare, or visual impairment than were those who received placebo. Noninfectious uveitis is a group of vision-threatening diseases that are characterized by intraocular inflammation; it can occur as a syndrome isolated to the eye or in association with a systemic condition. Uveitis has an estimated incidence of 17 to 52 cases per 100,000 person-years 1 and is estimated to cause 10 to 15% of cases of blindness in Western countries. 2 , 3 Glucocorticoids remain the mainstay of therapy despite their well-known ocular and systemic adverse effects. 4 – 6 Thus, there is a large unmet medical need for and a great interest in identifying more effective, glucocorticoid-sparing therapies, ideally targeting specific mediators of the . . .